Colorectal carcinogenesis is a progressive multistep process involving the sequential accumulation of genetic alterations in tumor suppressor genes and oncogenes. Downregulated by oncogenes 1 (Dro1/Ccdc80) has been shown to be a potent tumor suppressor of colorectal carcinogenesis in the genetic Apc Min/+ mouse model. In Apc Min/+ mice, loss of DRO1 strongly increases colonic tumor multiplicity and leads to the regular formation of adenocarcinoma in the colon. To investigate DRO1's role in chemically induced as well as inflammation-associated colorectal carcinogenesis, the effect of Dro1 inactivation was studied in mice subjected to the carcinogen azoxymethane (AOM) and upon combined treatment with AOM and the proinflammatory agent dextran sodium sulfate (DSS), respectively. Loss of DRO1 increases multiplicity of preneoplastic aberrant crypt foci and colonic tumors upon administration of AOM. Combined treatment with AOM and DSS leads to increased colonic tumor number and promotes formation of adenocarcinoma in the colon. Moreover, Dro1 inactivation aggravates histological signs of acute and chronic DSS-induced colitis, strongly enlarges the size of ulcerative lesions in the intestinal lining, and exacerbates clinical signs and morbidity by DSS. Our results demonstrate DRO1 to be a strong tumor suppressor in the chemically induced colon carcinogenic mouse model. Additionally, we demonstrate DRO1 to inhibit colitis-associated colon cancer formation and uncover a novel putative role for DRO1 in inflammatory bowel disease.
Introduction
Colorectal cancer (CRC) is the third most common cancer in the world and constitutes a major cause of tumor-related morbidity and mortality in the industrialized world (1) . To the current understanding, CRC evolves from adenomatous precursor lesions in a multistep process that involves multiple independent mutational events in tumor suppressor genes and oncogenes resulting in the perturbation of critical signaling pathways controlling cellular metabolism, proliferation, differentiation and survival (2) . Sporadic CRC develops spontaneously or as a result of prolonged inflammation of the colonic epithelium such as seen in ulcerative colitis and Crohn's disease, the two major forms of human inflammatory bowel disease (IBD) (2) (3) (4) .
To study the pathogenesis of CRC, several experimental protocols for the chemical induction of colon tumors in mice have been developed. The most successfully used chemical carcinogen is azoxymethane (AOM), which induces DNA mispairings by alkylation of the DNA (5) and causes formation of colon tumors within 30 weeks when injected repeatedly (6) . Tumors induced by AOM develop predominantly in the distal colon and exhibit many histopathologic features of human CRC (7) . Moreover, at the molecular level, AOM-induced tumors reflect human CRC in many aspects, e.g. they frequently carry mutations of the β-catenin gene (8) and show dysregulated levels of APC (9) and k-Ras (10) . However, in contrast to the human disease, invasiveness and metastatic properties are rarely observed (7, 11) , as AOM is mainly a tumor-initiating agent.
Investigation of inflammation-associated CRC is allowed by a modification of the AOM-based model. Here, AOM application is combined with subsequent treatment with dextran sodium sulfate (DSS) in drinking water, a synthetic sulfate polysaccharide that is extremely toxic to mouse colon epithelium and induces severe colitis (12) . A very potent protocol that leads to the formation of numerous large tumors within 10 weeks comprises a single AOM injection followed by three cycles of DSS application (6, 13, 14) . The repeated treatment with DSS produces chronic colitis, as seen in ulcerative colitis and Crohn's disease, which strongly promotes tumor progression (13, 15, 16) .
Previously, we identified DRO1 (downregulated by oncogenes 1) as a potent tumor suppressor of colorectal carcinogenesis (17) . DRO1 has been shown to be downregulated in most CRC cell lines and in the majority of primary human CRC specimens (18) . In Apc Min/+ mice, a mouse model of intestinal tumorigenesis which is hampered by the fact that tumors develop predominantly in the small intestine and progression to adenocarcinoma is a very rare event, loss of DRO1 strongly increases colorectal tumor incidence and leads to the regular formation of adenocarcinoma in the colon (17) . In normal colon epithelium and colon tumors from Apc Min/+ mice, depletion of DRO1 increases ERK1/2 phosphorylation and induces oncogenic c-myc activation (17) ; both factors are known to drive colorectal carcinogenesis in Apc Min/+ mice (19) . Recently, DRO1 has also been implicated in controlling expression of E-cadherin. Loss of E-cadherin is known to be one of the hallmarks of epithelial-mesenchymal transition (EMT), a process important during cancer invasion and metastasis (20, 21) . DRO1 has been shown to positively regulate expression of E-cadherin in thyroid cancer cells, mouse embryonic fibroblasts and in papillary thyroid carcinoma from tumor-prone ret/ PTC1 mice (22, 23) , suggesting a possible role for DRO1 in counteracting EMT and tumor metastatic behavior.
To investigate the effect of DRO1 loss on chemically induced colorectal carcinogenesis, we subjected Dro1 knockout mice (Dro1
−/−
) to six repeated injections of AOM and analyzed the consequences on tumor development in the colon. To elucidate the role of DRO1 in inflammation-associated tumor growth, we combined administration of AOM with application of DSS in drinking water. Moreover, to elucidate DRO1's role in EMT, we investigated the influence of DRO1 loss on the expression of E-cadherin and additional markers for EMT in colon tumors from Apc Min/+ mice.
Material and methods

Animals
Dro1 −/− and Dro1 fl/fl mice were generated as described previously (17 
Tumor scoring
The colon was excised, rinsed with PBS (pH 7.4) to remove fecal material, placed on a piece of filter paper, opened longitudinally, laid open and fixed in 4% buffered formaldehyde solution. Tumor number and their maximum diameter were determined under a dissecting microscope at ×10 magnification. The colon and rectum were scored as "colon."
Analysis of ACF
Colon samples were stained with methylene blue as described before (24) and analyzed by light microscopy at 100-fold magnification and transillumination.
Histology
Histological assessment was performed by a pathologist (J.N.) who was blinded to the experimental protocol (J.N.). Histological sections of the formalin-fixed and paraffin-embedded tissue samples were stained with haematoxylin-eosin (H&E) according to a standard protocol. For tumor histology, colon tumors sized ≥2 mm in diameter were resected, including adjacent normal tissue, dehydrated and embedded in paraffin and 4-µm tissue sections cut in parallel with the mucosal surface and stained with H&E. Histopathologic analysis of neoplastic lesions was performed using standard criteria according to the classification of human adenomas of the colon and the assessment of the degree of dysplasia. The diagnosis intramucosal adenocarcinoma was made for lesions with high-grade dysplasia/intraepithelial neoplasia in combination with focal invasion of the lamina propria mucosae, cytologic features such as cribriform architecture with intraluminal accumulation of tumor and inflammatory cell debris (dirty necrosis) and desmoplastic stromal reaction. Adenocarcinomas invading through the lamina muscularis mucosae into the tela submucosa were classified as invasive adenocarcinoma (25) . For subsequent analysis, invasive adenocarcinoma and intramucosal adenocarcinoma were summarized under the diagnosis of adenocarcinoma.
Histopathologic analysis of colitis was performed using a score adopted from Kruschewski et al. (26) . In brief, signs of acute (mucosal integrity, infiltration of neutrophil granulocytes, cryptitis and mucosal edema) and chronic (mucosal transformation, round-cell infiltrates) inflammation were evaluated separately. Depending on the score, a distinction was made between low (1-4 points), moderate (5-8 points) and severe (9-12 points) inflammation. In addition to Kruschewski's scoring system, the degree of regenerative changes of the epithelium (low grade, moderate or high grade) and the distribution pattern of mucosal damage (focal versus diffuse) were determined semiquantitatively. Regenerative changes of the epithelium were classified by evaluation of the varying degrees of nuclear enlargement, hyperchromasia, nuclear stratification, presence of at least partial surface maturation, cytoplasmic basophilia, increased mitotic activity and mucus/goblet cell depletion according to standard protocols for assessment of human IBD (27) . The length of ulcerative lesions was measured under a light microscope at ×4 magnification.
Immunohistochemistry
Immunohistochemical staining was performed on 4-µm sections of formalinfixed, paraffin-embedded tissue samples. Slides were finally counterstained with Hematoxylin (Vector Laboratories). Reagents used for immunohistochemistry are displayed in Supplementary Table S1, available 
Immunoblotting
Protein lysates from mouse tissue samples were generated using M-PER mammalian extraction reagent (Thermo Scientific) and separated by electrophoresis in discontinuous SDS-polyacrylamide gels. The following antibodies were used for immunodetection: anti-ERK1/2 (Cell Signaling), 
PCR
Mice were genotyped by PCR analysis from genomic tail tip DNA as described previously (17) . RNA isolation was performed using Trizol reagent according to standard protocols. For quantitative RT-PCR, genomic DNA was removed from the RNA preparation using DNase I, Amplification Grade (Invitrogen). First-strand cDNA was generated using the SuperScript First-Strand cDNA Synthesis System (Invitrogen). Primer sequences are displayed in Supplementary Table S2 , available at Carcinogenesis Online.
Statistical analysis
To analyze significance of differences, two-tailed Student's t-test or twotailed Mann-Whitney U-test were performed (GraphPad Prism 4). P values ≤0.05 were considered to be statistically significant.
Results
DRO1 promotes AOM-induced tumorigenesis
For the study of AOM-induced colorectal carcinogenesis, 2-week-old Dro1 −/− and control mice were subjected to six intraperitoneal injections of AOM ( Figure 1A ). Necropsy was performed 16 weeks following the first AOM administration, and the colon was screened for the formation of preneoplastic aberrant crypt foci (ACF) and tumors.
Loss of DRO1 resulted in a dramatic increase in the number of ACF in the colon as demonstrated by methylene blue staining; mean number of ACF was 18.8 in Dro1
−/− mice versus 5.1 in controls (P ≤ 0.001; Figure 1B ). Detailed analysis of the number of aberrant crypts per focus showed that in Dro1 −/− mice, the total increase in ACF was mediated by a significant increase in small (ACF with 1-10 aberrant crypts per focus; P ≤ 0.001) as well as large ACF (ACF comprising more than 10 aberrant crypts; P ≤ 0.05; Figure 1C ). Microscopically, methylene blue-stained ACF in Dro1 −/− mice were similar to ACF in control mice ( Figure 1D ). Likewise, histopathologic examination revealed no differences between ACF from Dro1 −/− and control mice. Independent of the genotype, non-dysplastic ACF with hyperplasia of the intestinal epithelium were observed ( Figure 1D ).
Loss of DRO1 also had a strong effect on the formation of AOM-induced colonic tumors. Dro1 −/− mice showed a striking increase in tumor multiplicity in the distal colon compared with control mice; mean tumor number was 7.4 in Dro1 −/− mice versus 1.9 in controls (P = 0.004; Figure 1E ). In both genotypes, tumors located to the distal colon; the proximal colon was free of tumors. The increase in tumor burden in Dro1 −/− mice was mediated by a significant increase in both the number of small (≤2.5 mm) and large (˃2.5 mm) tumors ( Figure 1F ). However, Dro1 inactivation had no effect on mean tumor size (1.73 ± 0.91 mm in Dro1 −/− mice versus 1.69 ± 0.78 mm in controls; P = 0.85). Detailed histopathological analysis showed no differences between tumors from Dro1 −/− and control mice (Supplementary Figure 1 , available at Carcinogenesis Online); in both genotypes, ~60% of tumors were adenoma and ~40% had progressed to intramucosal adenocarcinoma (n = 5 tumors from 14 control mice and n = 32 tumors from 15 Dro1 −/− mice; Supplementary Table S3 , available at Carcinogenesis Online). Macroscopically, no metastases to lymph nodes, liver and lungs were identified.
DRO1 loss drives inflammation-associated colon carcinogenesis
To investigate whether Dro1 inactivation also promotes inflammation-associated colorectal tumor development, 8-week-old Dro1 −/− and control mice were treated with a single intraperitoneal AOM injection following three cycles of DSS administration in drinking water (Figure 2A) .
Twelve weeks after AOM application, two of the Dro1 −/− mice exhibited rectal prolapse of tumors, thus necropsy was performed on the whole cohort. Examination of the colon revealed a significant increase in tumor multiplicity upon DRO1 loss; mean tumor number was 12.0 in Dro1 −/− mice versus 1.7 in controls (P ≤ 0.05; Figure 2B and C). Formation of colon tumors was observed in all of the Dro1 −/− mice; in contrast, three of the nine control mice (~33%) were free of colon tumors. Moreover, in control mice, tumors located exclusively to the distal colon, whereas in two of the Dro1 −/− mice, neoplastic lesions were also present in the proximal colon (two proximal tumors in one Dro1 −/− mice, three proximal tumors in the other). Mean tumor diameter was unchanged by DRO1 loss (2.52 ± 1.35 mm in Dro1 −/− mice versus 2.19 ± 1.31 mm in controls; P = 0.11).
Histopathologic analysis of 12 colon tumors from nine control mice revealed six (50%) adenoma and six (50%) intramucosal adenocarcinoma ( Figure 2D ). In contrast, 44 of the 56 (~79%) colon tumors isolated from 8 Dro1 −/− mice were adenocarcinoma, the remaining 12 tumors (~21%) were adenoma ( Figure 2D) . Notably, 40 of the 44 (~91%) Dro1 −/− adenocarcinoma were classified as intramucosal adenocarcinoma, and four tumors (~9%) showed invasiveness into the tela submucosa ( Figure 2E ). Invasiveness was not observed for control tumors. Independent of the genotype, macroscopic examination revealed no visible metastases to lymph nodes, liver and lungs.
Dro1 inactivation aggravates morbidity and colitis by DSS
Loss of DRO1 not only promoted colonic carcinogenesis upon AOM/DSS treatment but also strongly aggravated morbidity and colitis by DSS. Upon the first and second DSS cycle, in which 2.6% DSS was administered, Dro1 −/− mice lost significantly more weight compared with controls ( Figure 3A) . Moreover, 7 of the 15 Dro1 −/− mice had to be sacrificed due to dramatic weight loss and bloody diarrhea (two Dro1 −/− mice upon the first DSS cycle; five Dro1 −/− mice upon the second DSS cycle). In contrast, control mice developed only mild diarrhea and showed no signs of severe illness; none of the control mice had to be sacrificed. To reduce morbidity in Dro1 −/− mice in the third DSS cycle, DSS concentration in drinking water was reduced to 2.0%. In consequence, none of the Dro1 −/− mice reached morbidity. Weight loss was still increased upon reduction of DSS in Dro1 −/− mice compared with controls; however, significance was not reached ( Figure 3A) . To study the effect of Dro1 inactivation on DSS-induced colitis in vivo, we performed colonoscopy on day 10 following the second (2.6% DSS) and third (2.0% DSS) DSS cycle and scored the colon for signs of colitis according to a protocol by (14) ; unfortunately, colonoscopy could not be performed earlier because of the poor condition of the Dro1 −/− mice. Upon 2.6% as well as 2% DSS, control mice presented a healthy colon with no signs of inflammation present at the time of colonoscopy (Table 1 
.0% DSS)).
To study the effect of DRO1 loss on DSS-induced colitis more in detail, 3-month-old Dro1 −/− and control mice were treated with 2.9% DSS for 3 days and necropsy was performed on day 3 following termination of DSS application. A detailed histopathologic examination of H&E-stained colon sections was carried out, and the lesions were scored for signs of acute and chronic inflammation according to a standard protocol (26) . Control mice showed only signs of moderate acute inflammation, whereas
Dro1
−/− mice had developed severe acute inflammation (Table 2, Figure 3B ). Chronic inflammation was low in control mice and moderate in Dro1 −/− mice (Table 2) . Moreover, the colonic epithelium of Dro1 −/− mice showed an increased degree of regeneration compared with controls (Table 2, Figure 3C ). Measurement of the length of DSS-induced lesions in H&E-stained colon sections revealed significantly larger mucosal ulcerations in Dro1 −/− mice compared with controls (P ≤ 0.001; Table 2, Figure 3D ). In control mice, ~13% of the mucosal surface was damaged; in Dro1 −/− mice, ~37% were affected (Table 2) .
To investigate whether DRO1 loss promotes susceptibility to DSS-induced ulcerative lesions in the intestinal epithelium by a reduction in cell-to-cell adhesion, we performed immunohistochemical staining for the cell adhesion proteins Occludin, Claudin 1 and E-Cadherin. We found no differences in protein level and location of Occludin, Claudin 1 and E-Cadherin between 
DRO1 loss has no effect on cellular proliferation, apoptosis and pERK1/2 activation in tumors induced by AOM
To investigate whether loss of DRO1 promotes chemically induced tumorigenesis by sustained-cellular proliferation and/ or changes in apoptosis, immunohistochemical staining for Ki67 and cleaved caspase-3 were performed on ACF and colon tumors from Dro1 −/− and control mice treated with AOM and AOM/DSS, respectively. No differences in the rate and distribution of proliferating as well as apoptotic cells were observed ( Supplementary  Figures 3 and 4 , available at Carcinogenesis Online). These findings are consistent with results obtained from colon tumors from Apc Min/+ mice (17) . Previously, we demonstrated Dro1 inactivation to induce phosphorylation of ERK1/2 in colon tumors from Apc Min/+ mice (17) . To investigate whether increased pERK1/2 levels are also Table 2 . Histological score of acute and chronic inflammatory activity and regeneration in the colon of Dro1 −/− and control mice. Dro1 −/− and control mice were treated with 2.9% DSS for 3 days, and necropsy was performed on day 3 following termination of DSS application DRO1 has no effect on the expression of markers for EMT in colon tumors from Apc Min/+ mice DRO1 has been shown to positively regulate expression of E-cadherin in thyroid cancer cells, mouse embryonic fibroblasts and in papillary thyroid carcinoma from tumor-prone ret/PTC1 mice (22, 23) . Loss of E-cadherin expression is known to be one of the hallmarks of EMT, a process important during cancer invasion and metastasis (20, 21 Figure 9 , available at Carcinogenesis Online).
Next, to investigate the impact of Dro1 inactivation on the expression of E-cadherin in an Apc Min/+ independent background, we performed immunohistochemistry for E-cadherin on colon tumors from Dro1 −/− and control mice treated with AOM and AOM/DSS, respectively. Consistent with our observations in Apc Min/+ mice, we could observe no effect of DRO1 inactivation on E-Cadherin protein level in the chemically induced tumors (Supplementary Figure 10 , available at Carcinogenesis Online).
Discussion
In the present study, we identify DRO1 as a tumor suppressor in chemically induced as well as inflammation-associated colorectal carcinogenesis. Loss of DRO1 increases multiplicity of preneoplastic ACF and colonic tumors upon administration of the carcinogen AOM. Also, combined treatment with AOM and the proinflammatory agent DSS leads to increased colonic tumor number and promotes formation of adenocarcinoma in the colon upon DRO1 loss.
Previously, we have also shown a tumor-suppressive role for DRO1 in colorectal carcinogenesis in Apc Min/+ mice (17), a genetic mouse model for the study of intestinal tumorigenesis (7) . In Apc Min/+ mice, inactivation of Dro1 results in a dramatic increase in colorectal tumor number and leads to the regular formation of adenocarcinoma (~35% of tumors) in the colon (17) . Recently, DRO1 has also been identified as a tumor suppressor in thyroid and ovarian carcinogenesis (23) .
Although DRO1 acts as a strong colonic tumor suppressor in chemically induced tumors and on the tumor-prone Apc Min/+ background, inactivation of DRO1 alone does not implicate intestinal tumor development (17) . Thus, the tumor-promoting effect of DRO1 deficiency in the colon depends on a second mutational hit which leads to the perturbation of critical signaling pathways and the initiation of tumor development.
Colorectal carcinogenesis is a progressive multistep process involving the sequential accumulation of genetic alterations in tumor suppressor genes and oncogenes (2) . Dro1 inactivation implicates a strong increase in the number of ACF in the colon upon treatment with AOM. ACF are the earliest visible morphological changes of the intestinal epithelium in colon carcinogenic rodent models (24, 28) . ACF are also prevalent in humans and are considered to be preneoplastic lesions in colorectal tumor formation (29) (30) (31) . The number of ACF has been shown to correlate with adenoma multiplicity (29) , and ACF were found to share many biochemical, genetic and morphological features with colon tumors (32) . Thus, our results give strong evidence for DRO1 to suppress tumor initiation and uncover a significant role for DRO1 in early tumor development.
Recently, we have demonstrated increased phosphorylation of ERK1/2 upon Dro1 inactivation in colon tumors from Apc Min/+ mice (17) . However, we found no effect of DRO1 loss on ERK1/2 activation in colon tumors induced by AOM, indicating DRO1 to modulate chemically induced colorectal carcinogenesis by other pathways then MAPK signaling. This discrepancy may be explained by the molecular differences between tumors induced by AOM and tumors on the genetic Apc Min/+ background. Treatment with AOM results in DNA mutations changing G:C to A:T (33) . Tumors induced by AOM carry highly frequent mutations in k-Ras (10), p53 (34) and the β-catenin gene (8) ; moreover, they constantly show dysregulated levels of APC (9) . In contrast, Apc Min/+ mice carry an inactivating mutation in one allele of the Apc tumor suppressor gene; tumor formation is induced by spontaneous loss of the heterozygous wild-type Apc allele (35) leading to the constitutive activation of the Wnt signaling pathway (36) . In Apc mouse models, spontaneous mutations in p53 as well as oncogenic h-and k-Ras activation have not been observed (37) (38) (39) .Therefore, loss of DRO1 might affect tumorigenesis in chemically induced tumors by different molecular mechanisms compared with Apc Min/+ tumors. Here, we also show an important role for DRO1 in inflammatory processes of the colonic epithelium. Dro1 inactivation aggravates histological signs of acute and chronic DSS-induced colitis and strongly enlarges the size of ulcerative lesions in the intestinal lining. In consequence, clinical signs and morbidity of DSS-induced colitis were strongly increased by DRO1 loss. DSSinduced colitis in mice is a useful model for IBD, as it exhibits many similarities to the corresponding human disease (40) . Thus, our results indicate a putative novel role for DRO1 in the pathogenesis of IBD.
In the inflammation-driven AOM/DSS model, DRO1 loss also facilitated formation of colorectal adenocarcinoma. Persistent inflammatory processes are supposed to be potent drivers of cancer development (41) . Ulcerative colitis and Crohn's disease are associated with an increased risk for CRC (3, 4) . The risk to develop IBD-associated CRC has been shown to correlate with the extension and duration of inflammation (3, 42) . Thus, in the AOM/DSS model, DRO1 loss might favor adenoma to carcinoma transition by excess inflammation of the colonic epithelium.
Recently, DRO1 has been shown to be a positive regulator of E-Cadherin expression in papillary thyroid carcinoma from ret/ PET1 mice and in mouse embryonic fibroblasts (23) . Moreover, in thyroid cancer cells, DRO1 has been found to induce E-cadherin expression by direct binding to its promoter (22) . In contrast, we could observe no effect of DRO1 inactivation on E-Cadherin level in colonic normal and neoplastic tissue from Apc Min/+ mice as well as tumors induced by AOM, indicating no regulatory function of DRO1 on the expression of E-Cadherin in the colon. Thus, the effect of DRO1 on the expression of E-Cadherin might be time and tissue dependent.
Also, Dro1 inactivation did not affect the expression of markers for EMT (N-cadherin, vimentin, fibronectin, snail, slug, zeb1 ) in colon tumors from Apc Min/+ mice. EMT constitutes the initiating event in invasiveness and metastatic behavior of epithelial cancers (43) . Given our results, a role for DRO1 in cancer invasiveness and metastasis in the colon is very unlikely. Consistently, we could observe no visible metastases upon DRO1 loss in both Apc Min/+ mice (17) and the chemically induced models. Here, we confirm DRO1's tumor-suppressive role in the colon in a chemically induced colon carcinogenic mouse model. Moreover, we demonstrate DRO1 to inhibit colitis-associated colon cancer formation and link DRO1 for the first time to IBD. Future studies are needed to elucidate the molecular mechanisms underlying DRO1's tumor-suppressive function and to investigate its role in IBD in detail. Supplementary Figures 1-10 , Tables S1-S4 and Videos 1 and 2 can be found at Carcinogenesis online.
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